Orchestra BioMed Holdings, Inc. (OBIO) Operating Margin
- Operating margin · 12 months: Value -181.36%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -181.36% | Operating income / revenue. Period ending 2026-06-30. $-57.99M ÷ $31.98M × 100 ≈ -181.36% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -57.99M USD | Operating Income (Loss) |
| Revenue | 31.98M USD | |
| Cost of products and services | (m) | |
| Research and development | 63.22M USD | Research and Development Expense |
| Selling, general and administration | 26.59M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-57.99M | $31.98M | (m) | $63.22M | $26.59M | -181.36% |
| 2026-03-31 | $-54.96M | $32.72M | (m) | $60.48M | $27.02M | -167.96% |
| 2025-12-31 | $-51.81M | $33.48M | (m) | $58.19M | $26.91M | -154.73% |
| 2025-09-30 | $-75.24M | $2.82M | (m) | $52.33M | $25.53M | -2669.91% |
| 2025-06-30 | $-71.27M | $2.94M | (m) | $49.90M | $24.09M | -2420.75% |
| 2025-03-31 | $-68.80M | $2.89M | (m) | $47.17M | $24.30M | -2383.89% |
| 2024-12-31 | $-64.30M | $2.64M | (m) | $42.80M | $23.93M | -2437.49% |
| 2024-09-30 | $-60.10M | $2.65M | (m) | $40.34M | $22.21M | -2270.68% |
| 2024-06-30 | $-58.29M | $2.08M | (m) | $37.31M | $22.89M | -2803.61% |
| 2024-03-31 | $-54.38M | $2.22M | (m) | $34.68M | $21.74M | -2454.15% |
| 2023-12-31 | $-51.51M | $2.76M | (m) | $33.82M | $20.26M | -1866.16% |
| 2023-09-30 | $-19.28M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-14.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-9.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-3.08M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-2.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-1.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-734.76K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-394.76K | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |